Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Gabather AB (5J2) Stock Price & Analysis

0 Followers

5J2 Stock Chart & Stats

€0.02€0.01(50.00%)
At close: 2:00 AM GMT+2
€0.05€0.1€0.15Oct 5Nov 1Dec 29Jul 14
Day’s Range
EUR 0.01 - EUR 0.01
52-Week Range
EUR 0.00 - EUR 0.02
Previous Close
EUR 0.01
Volume
N/A
Average Volume (3M)
0
Market Cap
EUR 1.05M
Enterprise Value
EUR 18.78M
Total Cash (Recent Filing)
EUR 3.69M
Total Debt (Recent Filing)
EUR 0
Price to Earnings (P/E)
―
Beta
3.32
Next Earnings
Nov 27, 2026 (Est.)
EPS Estimate
0
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Debt-Free Balance Sheet

A debt-free balance sheet avoids contractual interest costs and reduces creditor pressure, giving Gabather greater flexibility while it funds CNS drug development. This is a durable financial advantage, although it does not remove the need for operating capital.

Improving Cash Burn

The reduction in cash burn indicates some progress in controlling resource consumption, which could extend financial runway relative to earlier periods. If sustained, better cash discipline may support continued research activity and reduce the pace of future funding requirements.

Focused CNS Drug Development

Gabather has a clearly defined development focus centered on GABA-A receptor candidates for CNS disorders. A specialized small-molecule pipeline can concentrate research resources and scientific expertise, creating a coherent platform for advancing multiple candidates over time.

Bears Say

No Demonstrated Revenue

Zero revenue means Gabather has not yet established commercial product sales or an operating revenue base to fund research internally. This leaves future progress dependent on successful development, partnering, or financing rather than recurring business cash inflows.

Persistent Cash Consumption

Continued negative operating and free cash flow shows that the business consumes substantial cash while advancing its pipeline. Without revenue inflows, this pattern creates an ongoing requirement for external financing and can constrain the pace or scope of future development.

Capital Erosion

Periods of negative equity demonstrate that accumulated losses have materially eroded the capital base. Although TTM equity has turned positive, its modest level relative to ongoing losses leaves limited balance-sheet resilience and increases sensitivity to future financing needs.

5J2 FAQ

What was Gabather AB’s price range in the past 12 months?
Gabather AB lowest stock price was €0.00 and its highest was €0.02 in the past 12 months.
What is Gabather AB’s market cap?
Gabather AB’s market cap is €1.05M.
When is Gabather AB’s upcoming earnings report date?
Gabather AB’s next earnings report is estimated for Nov 27, 2026 (not yet confirmed), which is in 14 days.
How were Gabather AB’s earnings last quarter?
Gabather AB released its earnings results on Aug 31, 2026. The company reported €0 earnings per share for the quarter.
Is Gabather AB overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Gabather AB pay dividends?
Gabather AB does not currently pay dividends.
What is Gabather AB’s EPS estimate?
Gabather AB’s EPS estimate is 0.00.
How many shares outstanding does Gabather AB have?
Gabather AB has 610,491,300 shares outstanding.
What happened to Gabather AB’s price movement after its last earnings report?
Gabather AB reported an EPS of €0 in its last earnings report. Following the earnings report the stock price went down -33.333%.
Which hedge fund is a major shareholder of Gabather AB?
Currently, no hedge funds are holding shares in DE:5J2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology